Is Chlorzoxazone + Paracetamol registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 4 valid registrations of Chlorzoxazone + Paracetamol, including PARAFON (250,300 mg,mg, Capsule, SAR 29.20); PARAXONE CAPSULE (250,300 mg,mg, Capsule, SAR 26.30); Paraxon (300,250 mg,mg, Capsule, SAR 42.90); RELAXON CAP (250,300 mg,mg, Capsule, SAR 27.75).

Active substances

Chlorzoxazone + Paracetamol

SFDA 4

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
PARAFON	250,300 mg,mg	Capsule · Oral use	30 Blister	SAR 29.20	Generic · Prescription	RIYADH PHARMA	Valid
PARAXONE CAPSULE	250,300 mg,mg	Capsule · Oral use	30 Blister	SAR 26.30	Generic · Prescription	Jazeera Pharmaceutical Industries (JPI)	Valid
Paraxon	300,250 mg,mg	Capsule · Oral use	90 Blister	SAR 42.90	Generic · Prescription	Jazeera Pharmaceutical Industries (JPI)	Valid
RELAXON CAP	250,300 mg,mg	Capsule · Oral use	30 Blister	SAR 27.75	Generic · Prescription	Jamjoom Pharmaceuticals Factory Company	Valid

Indications — CHI Daman Drug Formulary

LOW BACK PAIN

Components

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.